SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/19/19 Artemis Therapeutics, Inc. 10-Q 6/30/19 43:2.4M Z-K Global Ltd/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 307K 2: EX-10.1 Material Contract -- exhibit_10-1 HTML 37K 3: EX-31.1 Certification -- §302 - SOA'02 -- exhibit_31-1 HTML 19K 4: EX-32.1 Certification -- §906 - SOA'02 -- exhibit_32-1 HTML 16K 11: R1 Document and Entity Information HTML 49K 12: R2 Interim Condensed Consolidated Balance Sheets HTML 69K 13: R3 Interim Condensed Consolidated Balance Sheets HTML 36K (Parenthetical) 14: R4 Interim Condensed Consolidated Statements of HTML 37K Comprehensive Income (Loss) 15: R5 Interim Condensed Statements of Stockholders' HTML 40K Equity (Unaudited) 16: R6 Interim Condensed Consolidated Statement of Cash HTML 44K Flows (Unaudited) 17: R7 General HTML 26K 18: R8 Significant Accounting Policies HTML 34K 19: R9 Commitments and Contingencies HTML 19K 20: R10 Income Tax HTML 39K 21: R11 Warrants Issued to Investors HTML 20K 22: R12 Computation of Net Loss per Share HTML 41K 23: R13 Stock Capital HTML 89K 24: R14 Related Parties HTML 18K 25: R15 Subsequent Events HTML 17K 26: R16 Significant Accounting Policies (Policies) HTML 64K 27: R17 Income Tax (Tables) HTML 38K 28: R18 Warrants Issued to Investors (Tables) HTML 22K 29: R19 Computation of Net Loss per Share (Tables) HTML 40K 30: R20 Stock Capital (Tables) HTML 78K 31: R21 Commitments and Contingencies (Details) HTML 19K 32: R22 Income Tax (Narrative) (Details) HTML 21K 33: R23 Income Tax (Schedule of Deferred Income Taxes) HTML 22K (Details) 34: R24 Income Tax (Schedule of Net Operating Loss HTML 19K Carryforwards) (Details) 35: R25 Warrants Issued to Investors (Details) HTML 20K 36: R26 Computation of Net Loss per Share (Schedule of HTML 32K Calculation of Basic Loss Per Share) (Details) 37: R27 Stock Capital (Narrative) (Details) HTML 77K 38: R28 Stock Capital (Summary of Stock Option Activity) HTML 51K (Details) 39: R29 Stock Capital (Summary of Stock Option Exercise HTML 40K price) (Details) 40: R30 Related Parties (Narrative) (Details) HTML 25K 42: XML IDEA XML File -- Filing Summary XML 71K 41: EXCEL IDEA Workbook of Financial Reports XLSX 37K 5: EX-101.INS XBRL Instance -- atms-20190630 XML 744K 7: EX-101.CAL XBRL Calculations -- atms-20190630_cal XML 70K 8: EX-101.DEF XBRL Definitions -- atms-20190630_def XML 208K 9: EX-101.LAB XBRL Labels -- atms-20190630_lab XML 423K 10: EX-101.PRE XBRL Presentations -- atms-20190630_pre XML 322K 6: EX-101.SCH XBRL Schema -- atms-20190630 XSD 88K 43: ZIP XBRL Zipped Folder -- 0001178913-19-002217-xbrl Zip 65K
☑ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
DELAWARE
|
84-1417774
|
(State or other jurisdiction of
|
(I.R.S. Employer Identification No.)
|
incorporation or organization)
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
ATMS
|
OTCQB
|
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
|
|
PAGE
|
|
|
|
4 | ||
|
|
|
4 | ||
|
|
|
|
5 | |
6 | ||
7 | ||
|
|
|
|
9
|
|
|
|
|
|
10 | |
|
|
|
21 | ||
|
|
|
24 | ||
|
|
|
25 | ||
25 | ||
|
|
|
26 |
PAGE
|
|
5 | |
6 | |
9 | |
10-20
|
|
As of
June 30, |
As of
December 31,
|
||||||||||
|
Note
|
2019
(Unaudited)
|
2018
(Audited)
|
|||||||||
|
||||||||||||
ASSETS
|
||||||||||||
|
||||||||||||
Current assets
|
||||||||||||
Cash and cash equivalents
|
7
|
7
|
||||||||||
Other accounts receivable and prepaid expenses
|
31
|
20
|
||||||||||
Total current assets
|
38
|
27
|
||||||||||
|
||||||||||||
TOTAL ASSETS
|
38
|
27
|
||||||||||
|
||||||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||||||
|
||||||||||||
Current liabilities
|
||||||||||||
Accrued expenses and other payables
|
154
|
161
|
||||||||||
Derivative warrant liabilities
|
7B
|
|
-
|
163
|
||||||||
Total current liabilities
|
154
|
324
|
||||||||||
|
||||||||||||
Long term liabilities
|
||||||||||||
Related Parties
|
8
|
100
|
-
|
|||||||||
Total Liabilities
|
254
|
324
|
||||||||||
|
||||||||||||
Shareholders’ equity
|
||||||||||||
Series A Convertible Preferred stock, $0.01 par value - Authorized: 10,000,000 shares; issued and outstanding: 453 shares as of June 30, 2019 and December 31, 2018
|
(*
|
)
|
(*
|
)
|
||||||||
Series C Convertible Preferred stock, $0.01 par value - Authorized: 250 shares; issued and outstanding: 250 shares as of June 30, 2019 and December 31, 2018
|
(*
|
)
|
(*
|
)
|
||||||||
Common stock, $0.01 par value - authorized: 51,000,000; issued and outstanding: 5,153,461 as of June 30, 2019 and December 31, 2018
|
52
|
52
|
||||||||||
Additional paid in capital
|
7
|
1,898
|
1,571
|
|||||||||
Accumulated deficit
|
(2,166
|
)
|
(1,920
|
)
|
||||||||
Total stockholders' equity
|
(216
|
)
|
(297
|
)
|
||||||||
|
||||||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
38
|
27
|
Six Months Ended
June 30, |
Three Months Ended
|
|||||||||||||||||||
2018
|
2019
|
2018
|
||||||||||||||||||
Note
|
(Unaudited)
|
(Unaudited)
|
||||||||||||||||||
Research and development expenses
|
-
|
129
|
-
|
58
|
||||||||||||||||
General and administrative
|
90
|
383
|
70
|
154
|
||||||||||||||||
Operating (loss)
|
(90
|
)
|
(512
|
)
|
(70
|
)
|
(212
|
)
|
||||||||||||
Finance income
|
-
|
160
|
1
|
71
|
||||||||||||||||
Net loss
|
(90
|
)
|
(352
|
)
|
(69
|
)
|
(141
|
)
|
||||||||||||
Net loss per share, basic and diluted
|
6
|
(0.01
|
)
|
(0.06
|
)
|
(0.01
|
)
|
(0.02
|
)
|
|||||||||||
Weighted average number of common stock used in calculation of net loss per share:
|
||||||||||||||||||||
Basic and diluted
|
5,153,461
|
5,153,461
|
5,153,461
|
5,153,461
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated deficiency
|
Total
stockholders'
Equity
|
|||||||||||||||||||||||||||||||
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
|||||||||||||||||||||||||||||||
Balance as of March 31, 2019
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,894
|
(2,097
|
)
|
(151
|
)
|
|||||||||||||||||||||||
Share based compensation
|
-
|
-
|
-
|
-
|
-
|
-
|
4
|
-
|
4
|
|||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(69
|
)
|
(69
|
)
|
|||||||||||||||||||||||||
Balance as of June 30, 2019
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,898
|
(2,166
|
)
|
(216
|
)
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated deficiency
|
Total
stockholders'
Equity
|
|||||||||||||||||||||||||||||||
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
|||||||||||||||||||||||||||||||
Balance as of March 31, 2018
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,558
|
(1,618
|
)
|
(8
|
)
|
|||||||||||||||||||||||
Share based compensation
|
-
|
-
|
-
|
-
|
-
|
-
|
12
|
-
|
12
|
|||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(141
|
)
|
(141
|
)
|
|||||||||||||||||||||||||
Balance as of June 30, 2018
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,570
|
(1,759
|
)
|
(137
|
)
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated deficiency
|
Total
stockholders'
Equity
|
|||||||||||||||||||||||||||||||
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
|||||||||||||||||||||||||||||||
Balance as of December 31, 2018
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,571
|
(1,920
|
)
|
(297
|
)
|
|||||||||||||||||||||||
Adoption of new accounting Standards
|
-
|
-
|
-
|
-
|
-
|
-
|
319
|
(156
|
)
|
163
|
||||||||||||||||||||||||||
Share based compensation
|
-
|
-
|
-
|
-
|
-
|
-
|
8
|
-
|
8
|
|||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(90
|
)
|
(90
|
)
|
|||||||||||||||||||||||||
Balance as of June 30, 2019
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,898
|
(2,166
|
)
|
(216
|
)
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated deficiency
|
Total stockholders'
Equity
|
|||||||||||||||||||||||||||||||
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
|||||||||||||||||||||||||||||||
Balance as of December 31, 2017
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,457
|
(1,407
|
)
|
102
|
||||||||||||||||||||||||
Share based compensation
|
-
|
-
|
-
|
-
|
-
|
-
|
113
|
-
|
113
|
|||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(352
|
)
|
(352
|
)
|
|||||||||||||||||||||||||
Balance as of June 30, 2018
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,570
|
(1,759
|
)
|
(137
|
)
|
Six Months Ended
June 30, |
||||||||
2018
|
||||||||
Net cash used in operating activities
|
||||||||
Net (loss)
|
(90
|
)
|
(352
|
)
|
||||
Share based compensation expenses
|
8
|
113
|
||||||
Decrease (increase) in other accounts receivable and prepaid expenses
|
(11
|
)
|
25
|
|||||
Decrease in accrued expenses and other payables
|
(7
|
)
|
-
|
|||||
Change in the fair value of derivative warrant liability
|
-
|
(163
|
)
|
|||||
Net cash used in operating activities
|
(100
|
)
|
(377
|
)
|
||||
Cash flows from financing activities
|
||||||||
Related party proceeds
|
100
|
-
|
||||||
Cash flows from financing activities
|
100
|
-
|
||||||
Decrease in cash and cash equivalents
|
-
|
(377
|
)
|
|||||
Cash and cash equivalents at the beginning of the period
|
7
|
525
|
||||||
Cash and cash equivalents at the end of the period
|
7
|
148
|
Deferred tax assets:
|
||||||||
Deferred taxes due to carryforward losses
|
2,872
|
2,864
|
||||||
Valuation allowance
|
(2,872
|
)
|
(2,864
|
)
|
||||
Net deferred tax asset
|
-
|
-
|
Israel
|
4,840
|
4,799
|
||||||
United States (*)
|
8,374
|
8,385
|
||||||
13,214
|
13,184
|
Issuance
date |
Number of warrants
outstanding as
|
Exercise
price |
Exercisable
through |
||||||
|
|
||||||||
October 2017
|
275,000
|
$
|
2.00
|
October 2022
|
Six Months
Ended June 30
|
Three Months
Ended June 30
|
|||||||||||||||
2019
|
2018
|
2019
|
2018
|
|||||||||||||
Unaudited
|
Unaudited
|
|||||||||||||||
Net loss available to stockholders of the company
|
(90
|
)
|
(352
|
)
|
(69
|
)
|
(141
|
)
|
||||||||
Net loss attributable to stockholders of preferred shares
|
(13
|
)
|
(52
|
)
|
(10
|
)
|
(21
|
)
|
||||||||
|
||||||||||||||||
Net loss used in the calculation of basic loss per share
|
(77
|
)
|
(300
|
)
|
(59
|
)
|
(120
|
)
|
||||||||
|
||||||||||||||||
Net loss per share
|
(0.01
|
)
|
(0.06
|
)
|
(0.01
|
)
|
(0.02
|
)
|
||||||||
|
||||||||||||||||
Weighted average number of common stock used in the
calculation of net loss per share
|
5,153,461
|
5,153,461
|
5,153,461
|
5,153,461
|
For the Six months ended
|
||||||||||||
Number of stock options
|
Weighted average exercise price
|
Aggregate intrinsic value
|
||||||||||
Outstanding at beginning of period
|
250,716
|
0.83
|
54,002
|
|||||||||
Granted
|
-
|
-
|
-
|
|||||||||
Exercised
|
-
|
-
|
-
|
|||||||||
Cancelled
|
109,188
|
1.30
|
-
|
|||||||||
Outstanding at end of period
|
141,528
|
0.47
|
15,102
|
|||||||||
Options exercisable at period end
|
109,236
|
0.19
|
15,102
|
|||||||||
For the twelve months ended
|
||||||||||||
Number of stock options
|
Weighted average exercise price
|
Aggregate intrinsic value
|
||||||||||
Outstanding at beginning of period
|
334,168
|
0.95
|
||||||||||
Granted
|
98,528
|
1.30
|
||||||||||
Exercised
|
-
|
-
|
||||||||||
Cancelled
|
181,980
|
1.30
|
||||||||||
Outstanding at end of period
|
250,716
|
0.83
|
54,002
|
|||||||||
Options exercisable at period end
|
212,174
|
0.74
|
54,002
|
Exercise price
|
Stock options outstanding as of June 30,
|
Stock options outstanding as of December 31,
|
Weighted average remaining contractual life – years as of June 30,
|
Weighted average remaining contractual life – years as of December 31,
|
Stock options exercisable as of June 30,
|
Stock options exercisable as of December 31,
|
||||||||||||||||||||
$
|
2019
|
2018
|
2019
|
2018
|
2019
|
2018
|
||||||||||||||||||||
0.01
|
91,528
|
91,528
|
7.15
|
7.64
|
91,528
|
91,528
|
||||||||||||||||||||
1.30
|
-
|
60,660
|
-
|
8.61
|
-
|
60,660
|
||||||||||||||||||||
1.30
|
50,000
|
98,528
|
8.72
|
9.21
|
17,708
|
59,986
|
||||||||||||||||||||
0.83
|
141,528
|
250,716
|
7.67
|
8.46
|
109,236
|
212,174
|
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
|
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
101.1
|
|
The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 formatted in XBRL (eXtensible Business Reporting Language): (i) the Interim Condensed Consolidated Balance Sheets, (ii) the Interim Condensed Consolidated Statements of Comprehensive Loss, (iii) the Condensed Consolidated Statements of
Shareholders Equity, (iv) the Interim Condensed Consolidated Statements of Cash Flows and (v) related notes to these financial statements, tagged as blocks of text and in detail.*
|
|
|
||
|
ARTEMIS THERAPEUTICS, INC.
|
||
|
|
||
Dated: August 19, 2019
|
By: |
/s/ Chanan Morris
|
|
|
|||
|
Chief Financial Officer
|
||
|
(Principal Executive Officer and Principal Financial
and Accounting Officer)
|
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
3/15/28 | ||||
6/30/21 | ||||
Filed on: | 8/19/19 | |||
8/13/19 | ||||
For Period end: | 6/30/19 | NT 10-Q | ||
5/15/19 | 10-Q | |||
4/4/19 | ||||
3/31/19 | 10-Q | |||
3/22/19 | ||||
1/10/19 | ||||
12/31/18 | 10-K, NT 10-K | |||
12/15/18 | ||||
8/22/18 | ||||
8/10/18 | ||||
6/30/18 | 10-Q | |||
3/31/18 | 10-Q | |||
3/15/18 | 4 | |||
2/1/18 | ||||
12/31/17 | 10-K, 10-K/A | |||
10/23/17 | 4 | |||
9/1/17 | ||||
8/1/17 | ||||
12/16/16 | ||||
8/23/16 | 3 | |||
8/22/16 | ||||
8/19/16 | ||||
5/31/16 | ||||
4/19/16 | ||||
9/30/03 | 10QSB | |||
7/8/03 | 8-K | |||
4/22/97 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/03/22 Manuka, Inc. 10-K 12/31/21 44:2.6M Z-K Global Ltd./FA 3/30/21 Manuka, Inc. 10-K 12/31/20 42:2M Z-K Global Ltd./FA |